The estimated Net Worth of Kenneth Allen Myszkowski is at least $25 Milione dollars as of 6 March 2024. Mr. Myszkowski owns over 40,000 units of Arrowhead Pharmaceuticals stock worth over $8,388,564 and over the last 14 years he sold ARWR stock worth over $14,854,583. In addition, he makes $1,741,550 as Chief Financial Officer at Arrowhead Pharmaceuticals.
Kenneth has made over 29 trades of the Arrowhead Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 40,000 units of ARWR stock worth $1,407,600 on 6 March 2024.
The largest trade he's ever made was selling 81,875 units of Arrowhead Pharmaceuticals stock on 17 January 2019 worth over $1,191,281. On average, Kenneth trades about 17,594 units every 107 days since 2010. As of 6 March 2024 he still owns at least 400,600 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Mr. Myszkowski stock trades at the bottom of the page.
Kenneth Allen Myszkowski serves as Chief Financial Officer of the Company. Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.
As the Chief Financial Officer of Arrowhead Pharmaceuticals, the total compensation of Kenneth Myszkowski at Arrowhead Pharmaceuticals is $1,741,550. There are 1 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.
Kenneth Myszkowski is 53, he's been the Chief Financial Officer of Arrowhead Pharmaceuticals since 2010. There are 11 older and 5 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.
Kenneth's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 20 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone e Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: